You are not logged in.

Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis

Clark, R. A., Berry, N. M., Chowdhury, M. H., McCarthy, A. L., Ullah, S., Versace, V. L., Atherton, J. J., Koczwara, B. and Roder, D. 2016, Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis, Internal medicine journal, vol. 46, no. 11, pp. 1297-1306, doi: 10.1111/imj.13201.

Attached Files
Name Description MIMEType Size Downloads

Title Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis
Author(s) Clark, R. A.
Berry, N. M.
Chowdhury, M. H.
McCarthy, A. L.
Ullah, S.
Versace, V. L.ORCID iD for Versace, V. L. orcid.org/0000-0002-8514-1763
Atherton, J. J.
Koczwara, B.
Roder, D.
Journal name Internal medicine journal
Volume number 46
Issue number 11
Start page 1297
End page 1306
Total pages 10
Publisher Wiley
Place of publication London, Eng.
Publication date 2016-11
ISSN 1445-5994
Keyword(s) cardiology
cardiotoxicity
chemotherapy
heart failure
oncology
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
BREAST-CANCER
CARDIOVASCULAR TOXICITY
DYSFUNCTION
MANAGEMENT
THERAPY
CARE
Summary BACKGROUND: Cardiotoxicity resulting in heart failure is a devastating complication of cancer therapy. A patient may survive cancer only to develop heart failure (HF), which has a higher mortality rate than some cancers.

AIM: This study aimed to describe the characteristics and outcomes of HF in patients with blood or breast cancer after chemotherapy treatment.

METHODS: Queensland Cancer Registry, Death Registry and Hospital Administration records were linked (1996-2009). Patients were categorised as those with an index HF admission (that occurred after cancer diagnosis) and those without an index HF admission (non-HF).

RESULTS: A total of 15 987 patients was included, and 1062 (6.6%) had an index HF admission. Median age of HF patients was 67 years (interquartile range 58-75) versus 54 years (interquartile range 44-64) for non-HF patients. More men than women developed HF (48.6% vs 29.5%), and a greater proportion in the HF group had haematological cancer (83.1%) compared with breast cancer (16.9%). After covariate adjustment, HF patients had increased mortality risk compared with non-HF patients (hazard ratios 1.67 (95% confidence interval, 1.54-1.81)), and 47% of the index HF admission occurred within 1 year from cancer diagnosis and 70% within 3 years.

CONCLUSION: Cancer treatment may place patients at a greater risk of developing HF. The onset of HF occurred soon after chemotherapy, and those who developed HF had a greater mortality risk.
Language eng
DOI 10.1111/imj.13201
Field of Research 119999 Medical and Health Sciences not elsewhere classified
1103 Clinical Sciences
1117 Public Health And Health Services
Socio Economic Objective 929999 Health not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Royal Australasian College of Physicians
Persistent URL http://hdl.handle.net/10536/DRO/DU:30089195

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 28 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 23 Nov 2016, 08:14:18 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.